Chantix Side Effects

Chantix side effects have been found to possibly cause heart attack and stroke in victims, especially in people with cardiovascular disease, often associated with cigarette smoking.

New studies indicate that the smoking cessation drug Chantix may be linked to a significantly increased risk of severe side effects among patients. Chantix has been on the market since 2006, when the FDA approved the drug via a "priority review." This means that Chantix was subjected to only a six-month review period, rather than the usual ten months, because of the drug's demonstrated effectiveness in clinical trials and perceived lack of safety issues. Unfortunately, information about potential Chantix side effects is finally being revealed, indicating that the FDA's approval may have been premature. Chantix is a prescription smoking cessation drug, which is used to treat smoking addiction in patients trying to quit. The active ingredient in Chantix is varenicline, and the drug functions by stimulating nicotine receptors more weakly than nicotine does. By doing so, Chantix can reduce nicotine cravings and decrease the pleasurable effects of cigarettes in order to aid in quitting smoking. Chantix is currently manufactured by pharmaceutical company, Pfizer, Inc.

As new Chantix side effect data is published, the dangers of the smoking cessation drug is garnering attention from researchers and the FDA. Although the FDA just issued a safety announcement in June 2011, warning patients and healthcare providers about the increased risk of side effects in a certain population of patients taking Chantix, further information has been gathered since, which calls for more Chantix side effect warnings. If you or a loved one has suffered from a potential Chantix side effect, contact an experienced Chantix attorney to discuss your legal options. You may have grounds to file a Chantix lawsuit against Pfizer in order to seek the financial compensation you deserve.

Potential Chantix Side Effects

Since Chantix garnered FDA approval in 2006, serious concerns have been raised about the safety of this medication due to information about Chantix side effects. Previously, FDA warnings were issued regarding the increased risk of heart side effects among patients taking Chantix who have cardiovascular disease. However, according to a new study published in the Canadian Medical Association Journal on July 4, 2011, the smoking cessation drug Chantix may increase the risk of serious cardiovascular events, including heart attack and stroke, by 72% even in patients without heart disease. The study was conducted by researchers at Johns Hopkins University and Wake Forest Baptist Medical Center. This alarming Chantix side effect data has led experts and researchers to request that the FDA issue a Chantix recall, removing Chantix from the U.S. market. The FDA has responded with assurances that the agency is evaluating this new Chantix information in order to determine whether or not a new Chantix side effect warning or further action is necessary.

Chantix FDA Warnings

In June 2011, the FDA issued a safety announcement warning patients and healthcare providers that the smoking cessation drug Chantix may be linked with an increased risk of certain cardiovascular adverse events in patients with heart disease. This FDA action was taken in response to a clinical trial in which serious side effects like heart attack were reported more frequently in patients who used Chantix compared to patients who were treated with a placebo. Along with this warning, the FDA advised patients and physicians to consider all benefits and risks of Chantix treatment before making the decision to use the drug in patients with heart disease. Although this warning was issued so recently, the new CMAJ study may make additional Chantix side effect warnings by the FDA a necessity.

The FDA and other organizations have taken significant action in the past to protect certain patients from the potential dangers of Chantix. In 2007, a year after Chantix was approved, the FDA's adverse event report system indicated that Chantix accounted for more occurrences of serious injury than any other drug. Among these Chantix side effects were irregular heartbeat, seizures, and blackouts, as well as serious psychiatric events like aggression and suicide. A year later, the Institute for Safe Medication Practices (ISMP) published its Chantix side effect findings, which resulted in the FDA ordering pilots with the Federal Aviation Administration to stop taking Chantix. Shortly afterward, the Federal Motor Carrier Administration, which oversees the bus and trucking industry, issued a similar Chantix ban for its commercial drivers. In light of information about severe Chantix side effects, even the Department of Defense prohibited certain aircraft and weapons personnel from using Chantix.

Chantix Attorneys for Side Effects

The potential side effects of the smoking cessation drug Chantix are severe and possibly even life-threatening. Although it is proven that smoking is dangerous to your health, drugs intended to help smokers quit should not inflict equally devastating harm upon patients. If you or a loved one has suffered from a serious injury which you believe to be associated with Chantix, contact a Chantix attorney to discuss the benefits of filing a Chantix lawsuit against Pfizer. The goal of Chantix lawsuits is to seek financial compensation for your injuries and medical expenses, as well as the pain and suffering endured by you and your family. Pharmaceutical companies like Pfizer are responsible for producing and distributing safe and effective drugs, and should be held accountable for any serious injuries sustained by consumers. Unfortunately, some drug companies intentionally conceal the more serious side effects of their drugs in order to make their product more appealing to the public. Victims of potential Chantix side effects are not at fault; with the help of a qualified Chantix lawyer, you can protect yourself from further harm and collect the compensation you deserve.






Prescription Drugs in The News